These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35367743)

  • 21. Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection.
    Jahangiri A; Owlia P; Rasooli I; Salimian J; Derakhshanifar E; Aghajani Z; Abdollahi S; Khalili S; Talei D; Eslam ED
    Sci Rep; 2021 Jan; 11(1):1914. PubMed ID: 33479293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of nosocomial Acinetobacter baumannii infections with a conserved immunogenic fimbrial protein.
    Mahmoudi Z; Rasooli I; Jahangiri A; Darvish Alipour Astaneh S
    APMIS; 2020 Jul; 128(7):476-483. PubMed ID: 32445596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-reactivity and immunotherapeutic potential of BamA recombinant protein from Acinetobacter baumannii.
    Vieira de Araujo AE; Conde LV; da Silva Junior HC; de Almeida Machado L; Lara FA; Chapeaurouge A; Pauer H; Pires Hardoim CC; Martha Antunes LC; D'Alincourt Carvalho-Assef AP; Moreno Senna JP
    Microbes Infect; 2021; 23(4-5):104801. PubMed ID: 33582283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic immunoprotection by Oma87 and Bap against Acinetobacter baumannii sepsis model.
    Mansouri M; Sadeghpoor M; Abdollahi M; Vafaei AJ; Jalali Nadoushan M; Rasooli I
    Int Immunopharmacol; 2023 Sep; 122():110650. PubMed ID: 37454632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of conserved cork and β-barrel domains of baumannii acinetobactin utilization protein in an animal model.
    Sangroodi YH; Rasooli I; Nazarian S; Ebrahimizadeh W; Sefid F
    Turk J Med Sci; 2015; 45(6):1396-402. PubMed ID: 26775400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with recombinant DcaP-like protein and AbOmpA revealed protections against sepsis infection of multi-drug resistant Acinetobacter baumannii ST2
    Fereshteh S; Ajdary S; Sepehr A; Bolourchi N; Barzi SM; Haririzadeh Jouriani F; Riazi-Rad F; Shahcheraghi F; Badmasti F
    Microb Pathog; 2023 Jan; 174():105882. PubMed ID: 36403713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection.
    Ainsworth S; Ketter PM; Yu JJ; Grimm RC; May HC; Cap AP; Chambers JP; Guentzel MN; Arulanandam BP
    Vaccine; 2017 Jun; 35(26):3387-3394. PubMed ID: 28522011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.
    McConnell MJ; Domínguez-Herrera J; Smani Y; López-Rojas R; Docobo-Pérez F; Pachón J
    Infect Immun; 2011 Jan; 79(1):518-26. PubMed ID: 20974823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenic reactivity of recombinant PKF and AbOmpA proteins as serum resistance factors against sepsis of Acinetobacter baumannii.
    Bolourchi N; Shahcheraghi F; Shirazi AS; Janani A; Bahrami F; Badmasti F
    Microb Pathog; 2019 Jun; 131():9-14. PubMed ID: 30930220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii.
    Bahey-El-Din M; Mohamed SA; Sheweita SA; Haroun M; Zaghloul TI
    Int J Med Microbiol; 2020 Apr; 310(3):151415. PubMed ID: 32156509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoprotective potential of in silico predicted Acinetobacter baumannii outer membrane nuclease, NucAb.
    Garg N; Singh R; Shukla G; Capalash N; Sharma P
    Int J Med Microbiol; 2016 Jan; 306(1):1-9. PubMed ID: 26614015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii.
    Zhang X; Yang T; Cao J; Sun J; Dai W; Zhang L
    Microb Pathog; 2016 Jul; 96():20-5. PubMed ID: 27133268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of Hybrid Transferrin Binding Protein Antigens for Protection Against Pathogenic Neisseria Species.
    Fegan JE; Calmettes C; Islam EA; Ahn SK; Chaudhuri S; Yu RH; Gray-Owen SD; Moraes TF; Schryvers AB
    Front Immunol; 2019; 10():247. PubMed ID: 30837995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acinetobacter baumannii outer membrane protein 34 elicits NLRP3 inflammasome activation via mitochondria-derived reactive oxygen species in RAW264.7 macrophages.
    An Z; Su J
    Microbes Infect; 2019; 21(3-4):143-153. PubMed ID: 30439507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of Different Methods for Preparing
    Li S; Chen DQ; Ji L; Sun S; Jin Z; Jin ZL; Sun HW; Zeng H; Zhang WJ; Lu DS; Luo P; Zhao AN; Luo J; Zou QM; Li HB
    Front Immunol; 2020; 11():1069. PubMed ID: 32655550
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunological evaluation of OMV(PagL)+Bap(1-487aa) and AbOmpA(8-346aa)+Bap(1-487aa) as vaccine candidates against Acinetobacter baumannii sepsis infection.
    Badmasti F; Ajdary S; Bouzari S; Fooladi AA; Shahcheraghi F; Siadat SD
    Mol Immunol; 2015 Oct; 67(2 Pt B):552-8. PubMed ID: 26277277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of Acinetobacter baumannii infection.
    García-Quintanilla M; Pulido MR; Pachón J; McConnell MJ
    PLoS One; 2014; 9(12):e114410. PubMed ID: 25485716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal immunization protects against Acinetobacter baumannii-associated pneumonia in mice.
    KuoLee R; Harris G; Yan H; Xu HH; Conlan WJ; Patel GB; Chen W
    Vaccine; 2015 Jan; 33(1):260-7. PubMed ID: 24699469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Response to Conjugates of Fragments of the Type K9 Capsular Polysaccharide of Acinetobacter baumannii with Carrier Proteins.
    Rudenko N; Karatovskaya A; Zamyatina A; Shepelyakovskaya A; Semushina S; Brovko F; Shpirt A; Torgov V; Kolotyrkina N; Zinin A; Kasimova A; Perepelov A; Shneider M; Knirel Y
    Microbiol Spectr; 2022 Oct; 10(5):e0167422. PubMed ID: 35980044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii.
    McConnell MJ; Rumbo C; Bou G; Pachón J
    Vaccine; 2011 Aug; 29(34):5705-10. PubMed ID: 21679737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.